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Abstract
Safaa Zahi R. Sader
STRUCTURAL AND DYNAMIC ANALYSIS OF WILD AND SPLICE VARIANTS
HUMAN µ-OPIOID RECEPTORS (G1 &G2) AND AMSACRINE RESISTANCE IN
HUMAN TOPOISOMERASE II ALPHA MUTANTS
2015-2016
Dr. Chun Wu, Ph.D.
Master of Science in Pharmaceutical Sciences
Morphine prescribing is limited by its high addiction tendency and other serious
effects. Recent animal’s biological studies on Mu 6TM splice variants, which mainly
include G1, G2 and Mu3, supported a high safety and potency profiles of IBNtxA as
potential alternative of Morphine. Nevertheless, there is no high-resolution structures of
these 6TM variants, and the detailed structural features and dynamic characteristics of these
splice variants remain elusive. We applied homology modeling and MD simulation to
probe the structural, dynamic and ligand binding differences between the wild type (7TM)
and two major truncated 6TM variants (G1 and G2). MD results underscored important
structural and dynamic differences between these receptors as well as prioritized ligand
affinity toward each receptor. The second project in this thesis involves in silico analysis
of mutational basis of Amsacrine resistance. Both R487K and E571K mutations were
studied. MD results indicated significant weakening of Amsacrine affinity in two mutants
in a consistent manner with the previous biological degree of resistance of two mutants.
Additionally, the intercalation loss and ligand ternary complex coordinate changes were
also revealed by MD simulation as possible causes of resistance.
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Chapter 1
Introduction to Computational Drug Design
Currently, developing new drug can cost approximately US 1.0 -1.9 billion.(1)
This cost mainly because the company need to synthesize and make thousands of
compounds to find the desired hit compound. Computational drug design and molecular
modelling offers enormous opportunity in pharmaceutical research due to precision and
cost effectiveness of algorithms used in these methods. The recent burst in
bioinformatics, genomics and structural information data had discovered plethora of new
targets and ligands. Considering the rapidly emerging new diseases and the cost and
effort imposed by traditional drug design and development, computational tools can
provide fast and reliable prediction of the pharmacological properties pertaining to
ligand and target.(2)
Drug discovery process is research intensive, time consuming and required
exorbitant funding resources. (2)Traditionally, the HTS is the widely used screening
method used by pharmaceutical companies where compounds synthesized and screened
against certain target via assay based tests. However, when it comes to testing millions of
compounds and the fact that many hits get stalled during clinical trials due to poor
pharmacokinetics profile or unwanted side effects, this traditional process becomes heavy
financial burden endured by the company and the cost of this research often transferred to
the patient.
Computer aided drug design employs different methodologies to explore the
biological processes and most importantly the ligand –protein binding. Some of methods
involves Bioinformatics tools, which provides the sources of data, required to start
computational jobs. For instance, homology modeling and sequence alignment of new
1

and existing targets is of pivotal importance in target validation and characterization.
Other tools involve ligand –protein bind g energy determination and visualization which
will be discussed in this chapter.
1.1 Computational Methods Used in this Thesis
1.1.1 Bioinformatics. Bioinformatics combines computer science, statistics and
mathematics, to analyze and interpret biological data. It has several applications in drug
design such as sequence alignment and analysis and homology modeling.
1.1.2. Homology modeling and sequence alignment. This technique is
extremely important in predicting the protein structure if the experimental X-ray
crystallography is not available. Furthermore, it is useful in refining the experimental
structure obtained through the crystallography or NMR to provide more precise structure
coordinates that can be further used for docking and simulation. Example tool is Prime
(Schrodinger) is a powerful and complete tool for generating accurate receptor models
for structure based drug design. Another function of Prime is sequence alignment of two
or multiple protein sequences and gives an accurate prediction of degree of homology
between the sequences from different species. This is crucial in structural modelling of
new target when desired specie’s crystal structure is only available for other species. For
example modelling desired human receptor based on experimentally available crystal
structure of Mouse receptor.
1.1.3. Molecular docking. Considered is essential tool in computer aided drug
design that aims to generate an accurate ligand-receptor complex structure especially
when the crystal structure is not resolved. Successful protein-ligand docking depends on
exhaustive exploration of space and effective scoring. Glide docking conducts complete

2

systematic search of conformational, orientational and positional space of the docked
ligand as can be seen in (figure 1).

Figure 1. (A) Definition of core and rotamer groups (B) Ligand diameter and center
definitions (C) Glide docking “funnel”, showing the Glide docking hierarchy.

3

Applications.
1. Ligand-protein complex construction.
2. Binding affinity calculations.
3. Drug discovery and lead optimization.
4. Virtual high throughput screening.
1.1.4 Binding energy calculations. In biological systems, ligands are
continuously binding and dissociating from the proteins as indicated by the following
chemical equation:
P+L

P.L

There are many methods to measure the ligand –protein binding affinity .Most or all
depends on measuring the binding as function of concentration of ligand or protein. For
example enzyme inhibition essays, Isothermal titration calorimetry (ITC) and other
essays. The binding reaction can also be analyzed in thermodynamics terms involving
free energy, enthalpy and entropy. For binding reaction at constant pressure, the
standards Gibbs free energy is given by:
∆Go = −RT ln KB
Moreover, this energy change can be broken down into energetic and entropic terms as
follow:
∆G° = ∆H − T∆S°
Since (H=E+PV) and P&V hardly change at biological systems:
∆G° ≈ ∆E − T∆S
∆E can be averaged over the range of molecular conformations that the free and bound
molecules explore due to thermal motions. Thus, the energy can be broken into number of
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contributions including, electrostatic interactions among charged and dipolar chemical
groups, hydrophobic interactions and intrinsic energetics of rotable bonds.
Developing an effective biding- free energy scoring function.
(OPLS-AA)Force fields development and

parameterizations(3).Force field

calculates the molecular system potential energy as a sum of individual energy terms:
E = E covalent+ E noncovalent
E covalent = E bond (Stretching) + E angle (Bending) + E (dihedral)
E noncovalent = E electrostatic + E van der Wales

Force filed based scoring function with implicit solvent (MM-GBSA). MMGBSA(4) stands for the Molecular Mechanics Generalized Born Surface Area. It is
fastest force-field based energy calculation obtained from energy difference between
complex and unbound ligand and protein. It combines the molecular mechanics terms
from force field with the solvation energy terms (implicit solvent), however, it lacks
the entropy term as follows:
ΔG=ΔEMM1+ΔGsolv2 - ΔT. ΔS
=ΔEbat3 + ΔEvdW + ΔEcoul + ΔGsolv, p
+ ΔGsolv, np - T ΔS

ΔEMM: gas phase molecular mechanics energy
ΔGsolv: polar and nonpolar terms
3
Ebat: covalent energy (bonds, angle, torsion).
1
2
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XP Glide docking and scoring.XP glide score (5)is a novel semi empirical scoring
function that uses unique water desolvation energy terms. Furthermore, new proteinligand structural binding terms to enhance prediction. The scoring function and docking
protocol were developed to reproduce the experimental binding affinities for asset of 198
complexes (RMSD of 2.26 and 1.73 Kcal/mol) over all and well docked ligands
respectively.
XP Glide Score = ΔEcoul + ΔEvdW+Ebind +Epenalty
Ebind=Ehyd_enclosure4 +Ehb_nn_motif5 +Ehb_cc_motif6 +EpI7 +
Ehb_pair +Ephobic_pair
Epenalty = Edesolv +Eligand_strain
1.1.5 Molecular dynamic simulations. This is one of the principal tools in
theoretical Biological activity. It measures time dependent interaction between biological
molecules such as protein-protein ligand-protein and ligand-DNA.MD simulation
generates information at the microscopic level including atomic positions and velocities.
Thus, it helps to visualize the macroscopic properties of system via microscopic simulation.
For example, to calculate changes in the binding free energy of a particular drug, or to
examine the energetics and mechanisms of conformational change.
Biological Applications includes:


Protein stability



Conformational changes



Protein folding

4

Ehyd_enclosure: hydrophobic Enclosure
Ehb_nn_motif: is the hydrogen bonds neutral-neutral motifs
6
Ehb_cc_motif: hydrogen bonds charged-charged motif
7
Epi: pi stacking and pi-cation interactions
5

6



Molecular recognition: protein, DNA membrane.



Ion transport



Drug design and structure determination of X-ray and NMR structures.

The molecular dynamics simulation method is based on Newton’s second law or the
equation of motion, Fi=mi.ai .From a knowledge of the force on each atom, it is possible
to determine the acceleration of each atom in the system. Integration of the equations of
motion then yields a trajectory that describes the positions, velocities and accelerations of
the particles as they vary with time. From this trajectory, the average values of properties
can be determined. Once the positions and velocities of each atom are known, the state of
the system can be predicted at any time in the future or the past. Molecular dynamics
simulations can be time consuming and computationally expensive. However, computers
are getting faster and cheaper. Simulations of solvated proteins are calculated up to the
nanosecond time scale; however, simulations into the millisecond regime have been
reported.
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Chapter 2
Structural and Dynamic Analysis of Wild and Splice Variants µ-Opioid Receptors
in Complex with Morphine and IBNtxA by Homology Modeling, Docking and All
Atoms Molecular Dynamic Simulation with Explicit Membrane
2.1 Introduction
Opioid drugs are a critical class of medications to treat acute and chronic pain, a
serious and costly public health issue (6-9). The prototypical opioid analgesic morphine
(Fig. 1A) is on the WHO Model List of Essential Medicines, the most important
medications needed in a basic health system. However, the safety and tolerability of
opioid analgesics is severely restricted due to side effects including sedation,
constipation, abuse liability and respiratory depression (10-14). The constipating effects
(15) in particular are common with chronic opioid use and can be dose-limiting, resulting
in inadequate pain relief (16), particularly in cancer pain management. Opioid misuse and
abuse is currently recognized as a major public health emergency, often referred to as the
“opioid epidemic” (17-19). Thus, based on the very large public health need for effective
analgesics, and substantial limitations confronting current prescription opioids, there is
pressing need for the development of novel opioid analgesics with more precisely
targeted mechanisms of action.

8

Figure 2. Chemical structures of morphine and IBNtxA.

Mu opioid receptor (MOR) are selectively activated by morphine, and most
opioid analgesics exert their effects via MOR signaling (20). MOR is a member of the Gprotein coupled receptor (GPCR) family, which is the largest and most diverse group of
membrane receptors, targets for a large proportion of drugs currently used in medicine.
Structurally, GPCRs all contain seven transmembrane (TM) domains with an
extracellular N-terminus and an intracellular C-terminus. Classically, once an agonist
binds, a conformational change in the receptor activates the α subunit of G-protein, which
exchanges GTP in place of GDP, causing the dissociation of the α subunit, the β+γ dimer,
and the receptor. Agonist binding to MOR-1 (e.g., by morphine), a Gαi/o-coupled GPCR
(21), induces suppression of adenylyl cyclase activity via the activated Gαi/o subunit,
thereby reducing intracellular cyclic AMP (cAMP) concentrations. The free β+γ dimer
can activate G protein-coupled inwardly rectifying potassium (GIRK) channels, altering
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cell membrane potentials. Additionally, MOR-1 has a dissociable signaling mechanism
via β-arrestin (22-26).
Since the cloning of the MOR gene, Oprm1, multiple splice variants have been
discovered. (27-31) The primary MOR variant, MOR-1, has been widely studied and its
high-resolution crystal structure has been obtained (32). In MOR-1, the TM domains
form a circular structure with the opioid-binding pocket located deep within the TM
region of the receptor (Fig. 3). Oprm1 splice variants include a variety of 3’ and 5’
splicing modifications, with similar patterns seen across a wide range of species,
including humans, rats, and mice (10). Three major sets of splice variants have been
identified. The first set are classical full-length variants, with all 7 TM domains, in which
3’ splicing leads to changes in only the tip of the intracellular tail; these modifications
may play important role in biased agonism (33). Because the remainder of these fulllength variants is the same, including all 7 TM domains, they should contain nearly
identical ligand-binding pockets. The second set of splice variants involves exon
skipping, producing only final protein products that contain a single TM domain.
Although these variants do not bind opioids directly, they help modulate opioid analgesia
by increasing expression of the full-length 7 TM variants through a chaperone-like action
(34). The final set of splice variants—and the focus of this research involves exon 11 and
its promoter, located about 30 k bases upstream of exon 1. These variants include exon
11 to the exclusion of exon 1, and thus are presumed to lack the first TM (TM1) domain
that exon 1 encodes, resulting in a truncated N-terminus (Fig. 2). Due to this truncation,
these MOR variants have been described as containing only 6 TM domains (35-37).
Three MOR variants (G1/1K/Mu3) completely lack the putative TM1 sequence, while the
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G2 variant retains only a small segment of the TM1 domain sequence. The complete or
partial absence of TM1 may change the ligand-receptor interaction, and thus opioid
analgesics. Indeed, the opioid analgesics profile of these truncated 6 TM/exon 11
(6TM/E11) variants is quite different from the full-length MOR-1, providing a target for
new agents with unique pharmacologic properties.

Figure 3. Abbreviated sequences of human MOR-1 (hMOR-1) splicing variants.
Transmembrane domains (TM1 and TM2) are highlighted in yellow. Residues 121-360
are not shown, as they are identical for all variants (see supporting info).

Various MOR-1 knockout mice models have provided important insights into
pharmacological profiles of the different spice variants (10). Two models in particular are
valuable: one MOR-1 knockout targeting exon 1, but still expressing exon 11-containing
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6 TM truncated variants (38), and an exon 11 knockout that lacks the 6TM variants
without appreciable changes in the expression levels of the full-length variants (39).
These two knockout models reveal different profiles of activity for different opioids
(Table 1). Based on the results of these studies, the analgesic effects of morphine are
totally dependent on the full-length MOR-1 and but unaffected by loss of the 6-TM
variants. Alternatively, the experimental drug 3-iodobenzoyl-6-naltrexamide (IBNtxA;
Fig. 1), a potent analgesic in wild-type mice (40), is unaffected by the loss of the fulllength MOR-1 splice variants (or delta and kappa1 receptors), but loss of the exon 11
variants removes its activity. This indicates that IBNtxA activity is primarily mediated
through its binding to 6TM/E11 MOR variants. Furthermore, IBNtxA is a potent
analgesic with an unusual pharmacologic profile. It is not only 10-fold more potent than
that of morphine (40,41), but also active in neuropathic/inflammatory pain models, which
is unusual for opioids (10). This is particularly useful in cancer pain management since
much of it is neuropathic in nature. Its adverse effect profile is also very attractive:
IBNtxA shows limited respiratory depression, reduced gastrointestinal slowing, and no
measurable abuse liability in a conditioned place preference experiment, and does not
produce physical dependence with chronic administration. These results raise the hope
that it might be possible to dissociate opioid analgesia from side effects and abuse
liability. Thus, targeting 6TM variants may yield important new analgesics in the future.
However, there is no high-resolution receptor/complex structure of the 6TM/E11 MOR
variants with morphine/IBNtxA, and it is not clear how the receptor truncation alters the
ligand binding properties of these receptors. In this study, we aim to decipher the
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structural and dynamic differences between splice variants and wild type when binding to
morphine and IBNtxA.

Table 1
MOR-1 knockout mouse models and opioid analgesia.
Exon 1 knockout a

Exon 11 knockout b

7 TM variants

Lost

Retained

6 TM variants

Retained

Lost

Lost

Retained

Retained

Lost

Properties
Mu receptor

Analgesia
Morphine
IBNtxA
a

Schuller et al. (38) b Pan et al. (39)

We applied homology modeling and MD simulations to understand the how
truncated and wild type receptors responded to Morphine and IBNtxA activations. Our
model was based on crystal structure of Mu-receptor bound to Morphinan antagonist (2.8
Å) as a template to construct the two splice variants G1 and G2 receptors as well as Mu
receptor wild type . The final homologs were obtained from GPCR-I-TASSER server
(42). Furthermore, we utilized Glide XP docking to dock Morphine and IBNtxA into wild
type and splice variants. Using the complexes from Xp docking, we constructed six
model systems of morphine and IBNtxA docked into three receptors and performed 100
ns MD simulations using consistent conditions for all six complexes. Results of 2D
interactions, protein Cα RMSFs and RMSDs data where supporting the premise that
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morphine and IBNtxA have completely different binding pockets and each one activated
its native wild type and related splice variant receptors differently. Predicted binding
energy calculations showed Morphine prioritize its wild type Over G1 and G2 .On the
other hand, IBNtxA showed higher affinity toward its wild type (G1) and 7TM compared
to G2. The 2D interaction comparisons among the three receptors complexes provided
additional evidence that splice variants interact with each ligand using different binding
pocket as indicated by genetic numbering. Collectively, truncated splice variants
responded differently from canonical Mu receptor, which provided new opportunities of
developing safe and effective morphine alternatives as indicated by in vivo and
computational results of G1 receptor modeling and IBNtxA pharmacological
characterizations data.
2.2 Computational Methods
2.2.1 Homology modeling of receptors. The FASTA sequences files of hMOR1, hMOR-1G1 and hMOR-1G2 were obtained from the Uniprot website(43). GPCR-ITASSER online service(42)was used to build their homology models . Out of five
homology models for each receptor obtained from the GPCR-I-TASSER online service,
the top 1 model was used in this study. The following PDB structures were used as
templates for building homology models by GPCR-I-TASSER: human delta opioid 7TM
receptor (PDB ID: 4N6H), Mu-opioid receptor in complex with a Morphinan antagonist
(PDB ID: 4DKL), chimeric protein of 5-HT1B-BRIL in complex with ergotamine (PDB
ID: 4IAR) and human delta opioid 7TM receptor (PDB ID: 4N6H).
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2.2.2 Glide docking.
Ligand preparation. The 3D structure of morphine and IBNtxA were prepared
using Maestro Elements. The 2D structures of morphine and IBNtxA were drawn using
the 2D sketcher. Then after, the ionization/tautomeric states were generated at pH=7
using the Epik which is based on the more accurate Hammett and Taft
methodologies(44). Only lowest ionization/tautomeric states were selected. Restrained
minimization was used to relax the ligand structure.
Protein structure preparation. Protein structures were prepared using
Schrodinger maestro protein preparation Wizard.(44) The charge state of preprocessed
protein was optimized at pH=7. Finally restrained minimization was performed to relax
the protein structure using OPLS3 force field (45).
Ligand docking. The binding sites of the prepared receptors were identified using
“binding site detection” module of Maestro. The site that is close to the N-terminal
binding pocket was used for docking, and the prepared ligands were docked into the Nterminal pocket using Glide XP scoring function with default procedures and parameters
(5,46). In details, the receptor grid required for docking process was generated using Van
der Waals scaling factor of 1 and partial charge cutoff 0.25. Docking was performed
using a ligand-centered grid using OPLS3 force field. Glide XP Dock performed a
comprehensive systematic search for the best receptor conformations and orientations to
fit the ligand. The docking results are included in Figure S2 of the supporting material.
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2.2.3 Molecular dynamic simulations. All six molecular dynamic simulation
systems were constructed using the prepared receptor-ligand complexes from the XP
docking. Each system was placed in a membrane of POPC lipids (47), and solvated in an
orthorhombic water box with a buffer distance of 8Å using SPC water model (48).
System was neutralized using Na+ ions, and was added with a salt concentration of 0.15
M NaCl. OPLS3 force field (45)was used to represent the receptor-ligand.
Relaxation and production runs. Using Desmond module, the system was first
relaxed using the default relaxation protocol for membrane proteins (49). This relaxation
protocol consists of eight stages: 1). Minimization with restraints on solute heavy atoms;
2) Minimization without any restraints; 3). Simulation with heating from 0 K to 300 K,
H2O barrier and gradual restraining; 4). Simulation under the NPT ensemble (constant
number of particles, constant pressure of 1 bar and constant temperature of 300 K,
Martyna-Tuckerman-Klein Nosé-Hoover chain coupling scheme (50)with H2O barrier
and with heavy atoms restrained; 5) Simulation under the NPT ensemble with
equilibration of solvent and lipids; 6). Simulation under the NPT ensemble with protein
heavy atoms annealing from 10.0 kcal/mol to 2.0 kcal/mol; 7). Simulation under the NPT
ensemble with Ca atoms restrained at 2 kcal/mol; and 8). Simulation for 1.5 ns under the
NPT ensemble with no restraints. After the relaxation, a 100.0 ns production run was
conducted under the NPT ensemble for each of the six systems using the default protocol.
M-SHAKE (51)was applied to constrain all bonds connecting hydrogen atoms, enabling a
2.0 fs time step in the simulations. The k-space Gaussian split Ewald method (52) was
used to treat long-range electrostatic interactions under periodic boundary conditions
(charge grid spacing of ~1.0 Å, and direct sum tolerance of 10–9). The cutoff distance for
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short-range non-bonded interactions was 9 Å, with the long-range van der Waals
interactions based on a uniform density approximation. To reduce the computation, nonbonded forces were calculated using an r-RESPA integrator (53) where the short range
forces were updated every step and the long range forces were updated every three steps.
Temperature was controlled using the Martyna-Tuckerman-Klein Nosé-Hoover chaincoupling scheme with a coupling constant of 1.0 ps. The trajectories were saved at 40.0
ps intervals for analysis.
Convergence of simulation. Convergence of simulation were inspected using the
root mean square deviation (RMSD) of the protein Cα atoms as a measure of system
equilibration. Protein RMSD is calculated as an average change of displacement of
selection of atoms for particular frame with respect to particular frame relative to the
initial frame structure. RMSD plots are shown in Figure S3 of the supporting material.
Receptor-ligand interaction analysis. Detailed receptor-ligand interaction was
analyzed using Simulation Interaction Diagram module of Maestro. The results are
included in Figure S7-S15 of the supporting material.
Trajectory clustering analysis. Protein backbone RMSD matrix was used in
hierarchical cluster average linkage method (54)to group the complex structures of the
simulation trajectory for each system. The merging distance cutoff used was set to be 2Å.
The centroid structure (i.e. the structure having the largest number of neighbors in the
structural family) was used to represent the family. The centroid structures of populated
structural families (>1% of total structure population) are shown in Figure S5-S6 of the
supporting material.

17

2.2.4 Binding energy calculations and decompositions methods. Molecular
Mechanism-General Born Surface Area (MM-GBSA) binding energies were calculated
for frames of the last 20ns of trajectory. VSGB 2.0 with implicit membrane model (4)
was used based on OPLS3 force field. The stepwise energy calculations as follows: (1)
Receptor alone (minimization).
(2) Ligand alone (minimization).(3) Receptor-ligand complex (minimization) (4) Ligand
extracted from optimized receptor-ligand complex (energy calculation)(5) Receptor
extracted from optimized receptor-ligand complex (energy calculation) .MMGBSA
binding energy decompositions in this study, we merge the original terms (Coulombic +
H-bond + GB solvation+ van der Waals + pi-pi packing + self-contact + lipophilic)(55)
into three components: Eelectrostatics, EvdW, and ELipophilic, where Eelectrostatics=(Hbond +
Ecoulomb +EGB_solvation), EvdW = (EvdW+Epi-pi +Eself-contact) and Elipophilic.
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2.3 Results
2.3.1 Homology modelling. Using the X-ray solved complex structure of mouse
MOR1 with a ligand (32), the homology models of the full length and truncated human
MOR-1 were obtained. The cartoon representations are shown in (Figure 3) from top
viewpoints. Clearly, the TM1 is completely missed in G1 receptor. It is interesting that
TM1 in 1G2 is only partially missed, because the protein sequence encoded by exon 11 in
hMOR-1G2 is predicted to be helical. However, this partial truncation should not change
much the ligand interaction with hMOR-1G2 from that with 1G1/K1/Mu3, because the
partially helix is located at intracellular part and not at extracellular part where ligands
bind to. It appears that TM1 is next the binding pocket, and thus its action on ligandreceptor interactions may come from indirect allosteric/chaperone-like effect.
Nonetheless, the partial or complete missing of TM1 can significantly change ligandreceptor interaction and dynamics, and thus changing the response of the receptors in
comparison to full-length version. The differences provide the base for designing more
selective ligands toward specific variant. These homology models can be good starting
structures for long time scale (μs) convention and replica exchange molecular dynamics
simulations to inspect these ligand-protein interaction and dynamics (56-61).
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Figure 4. Homolog models of (A) full length 7TM hMOR-1 receptor, (B) truncated
MOR-1G2 and (C) hMOR-1G1.

2.3.2 XP Glide docking. In order to build the Mu receptors complexes with
morphine and IBNtxA, we used Glide XP docking implemented in Schrodinger
(methodology). Each ligand (IBNtxA and morphine) was docked into three receptors and
binding poses were utilized as input structure to perform MD simulations. In addition, we
recorded the XP scores to get initial insight into the binding affinities of each ligand to
wild type and truncated variants (scores table is not shown). Morphine showed binding
energy of (-3.4 kcal) to full-length hMOR-1 which is slightly stronger than its binding to
the truncated G2 (-2.7 kcal/mol) and G1 (-3.0 kcal/mol). While the binding pose to the
full-length hMOR-1 is similar to hMOR-1G2 with a partial truncation of TM1, its
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binding pose is significantly different from its binding pose to hMOR-1G1 with a full
truncation TM1. In contrast, IBNtxA binds more strongly to hMOR-G2 and hMOR-G1
than to hMOR-1. The binding poses on hMOR-G2 and hMOR-G1 are different from its
binding pose to hMOR-1. It is also clear the binding energy of IBNtxA on G2/G1 is
stronger than the binding energy of morphine on the full-length hMOR1.
2.3.3 Ligand binding energy calculations. To characterize ligand binding
affinities toward different receptors , we performed the MMGBSA calculation (4) as
descripted in the method section and results are tabulated in (table 2). Morphine binding
to its wild type receptor 7TM showed ΔG of -73.6 kcal/mol compared to -66.4 kcal/mol
and -54.9 kcal/mol in case of G2 and G1 respectively. The order is 7TM>G2>G1,
morphine binds more favorable to 7TM than to G2 and G1 by -7.2 kcal/mol and -18.7
kcal/mol respectively. In contrast, IBNtxA binding to its wild type (G1) receptor
possessed the highest affinity (ΔG = -134.9 kcal) compared to -102.6/mol kcal and -118.9
kcal/mol for G2 and 7TM receptors respectively. The order is G1>7TM>G2, IBNtxA
binds more favorable to G1 than 7TM and G1 by -15.9 kcal/mol and -32.3 kcal/mol,
respectively. The ligand-receptor binding order from our MMGBSA binding energy data
is consistent with that of our XP scores, except that IBNtxA binds stronger to 7TM than
to G2. Therefore, MMGBSA data generally supports our early speculation that the
activity differences between morphine and IBNtxA might be caused by the differences in
the binding affinity. Our decomposition results indicated that, with all six complexes,
ΔVDW and ΔLIPO have the highest contribution compared to
ΔGBELE.However,significant variations observed were as follows:(1)with
Morphine,7TM has higher contribution from ΔVDW and ΔLIPO compared to those in

21

G1 and G2 .Whereas in G2,ΔGBELE contribution was the highest. (2)With IBNtxA ,
ΔVDW and ΔLIPO contributions was proportionate in all three receptors .However,
ΔGBELE contribution in G1 was significantly higher than 7TM which in turn was
higher than G2.These inter receptors variations in energy decomposition components can
be utilized to design effective future G1 and G2 candidates .Above results are tabulated
in table 2.

Table 2
MMGB-SA binding energies for both Morphine and IBNtxA complexes with the three
receptors.
LIGAND

Morphine

IBNtxA

RECEPTOR

7TM

G2

G1

7TM

G2

G1

ΔG1

-73.6±4

-66.4±6.5

-54.9±5.3

-119.0±5.4

-102.6±4.6

-134.9±6.6

ΔΔG2

0.0

7.2

18.7

15.9

32.3

0.0

ΔVDW3

-35.9±1.6

-27.9±8.4

-28.6±2.2

-53.4±2.3

-49.5±2.7

-52.9±1.7

ΔΔVDW

0.0

8.1

7.3

-0.5

3.4

0.0

ΔGBELE4

-2.5±3.6

-8.7±4.5

-2.2±2.5

-13.2±3.8

-6.9±3

-27.9±3.8

ΔΔGBELE

0.0

-6.2

0.3

14.7

21.1

0.0

ΔLIPO5

-35.1±1.0

-29.8±3.2

-24.0±1.6

-52.4±2.8

-46.3±2.3

-54.1±3.1

ΔΔLIPO

0.0

5.3

11.1

1.7

7.8

0.0

1

ΔG: MM-GBSA binding energy (Complex − Receptor − Ligand).
2
ΔΔG: relative binding energy with reference to active complex (wide type/G1).
3
ΔVDW: Change of van der Waals energy (vdW + Pi-pi stacking +Self-contact correction) in gas phase
upon complex formation
4
ΔGBELE: Change of electrostatic interactions (GB/Generalized Born electrostatic solvation energy+
ELE/Coulomb energy +Hydrogen-bonding) upon complex formation.
5
Change of lipophilic term (Lipophilic energy) upon complex formation.
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2.3.4 Morphine and IBNtxA binding poses. To identify the major binding pose,
we clustered the trajectory (54) as described in the method section. The representative
structure of the most abundance structure families are shown in Figure 4. Morphine
binding to its wild type and two splice variants adopted three slightly different poses
(Figure 4 A-C). IBNtxA binding to its wild type receptor and its splice variants structures
(Figure 4 D-F) also showed three distinct binding poses. To facilitate the comparison, we
superimpose the three complexes for the same ligand in Figure 5.
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Figure 5. Superposition of the most abundant complexes from the simulations. The
yellow, purple and cyan colors refer to wild type, G1 and G2 respectively.

2.3.5 Morphine and IBNtxA ligand 2D interaction data. To identify critical
residues contributing to morphine and IBNtxA bindings in each receptor, we did the
simulation interaction diagram analysis, which is implemented in DESMOND. The raw
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data are included in Figure S7-12 and the key interacting residues for each ligand were
tabulated in Table 3. For example, morphine-7TM 2D interaction conferred 18 different
residues from transmembranes 2, 3, 5, 6, and 7. Polar Residues are: ASP1162.50,
ASP1493.32, , ASN1523.35, TYR1503.33 ,SER1563.39 , LYS2355.40 , TRP2956.48 , CYS2946.47
HSD2996.52 CYS3237.37, TYR3287.42, TRP3207.34, , and hydrophobic residues:
ALA1192.53, MET1533.36 VAL2385.43 , LE2986.51 ,VAL3026.55, and ILE3247.38 .
Morphine binding to other two splice variants confers slightly different binding residues
compared to wild type. Similarly, IBNtxA binding to its wild type (G1) showed different
residues contacting the ligand compared to wild type. Figure 5 shows residues contacting
ligand more than 30% of simulation time. Clearly, we see there is no single interacting
residue of 7TM, G1 and G2 is identical for morphine. For IBNtxA, TRP7.34 is conserved
for 7TM and G2 and TYR7.42 is conserved for G2 and G1.
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Table 3
Morphine 2D interaction table with three different receptors. The three receptors are
aligned using Schrodinger maestro software, the genetic numbering was used to compare
residues in different receptors.
Morphine
IBNtxA
GEN_NO 7TM
G2
G1
7TM
G1
G2
2x50
ASP116
2x53
ALA119
ALA119
2x57
LEU42
2x60
GLN45
GLN26
GLN126 GLN26
GLN45
2x64
TYR130 TYR30
TYR49
e1
TRP135
TRP54
3X28
VAL64
3x29
ILE65
ILE146
ILE46
ILE65
3x32
ASP149
ASP68
ASP49
ASP149
ASP49
ASP68
3x33
TYR150 TYR69
TYR150 TYR50
TYR69
e2
THR139
3x35
ASN152 GLU150 ASN52
ASN152
3x36
MET153
MET53
MET153 MET53
MET72
3x37
PHE73
3X39
SER156
SER56
ASP218
E2
LEU121 THR139
E2
PHE123 LEU140
5X39
LEU234 LEU134
5X36
GLU150
5x40
LYS235 LYS154
LYS235
LYS154
5x43
VAL238
PHE191 VAL238 VAL138 VAL157
6x47
CYS294
CYS194
6x48
TRP295
TRP195 TRP295
TRP195
6x51
6x52
6x54
6x55
6x58
E3
7X34
7X37
7x38
7x41
7x42
7x46

ILE298
HSD299

ILE217
HSE218
TYR220
VAL221
LYS224

ILE198

TRP320
CYS323
ILE324

TRP239
CYS242
ILE243

TRP220
CYS223
ILE224

TYR328

TYR247

VAL302

SER231
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ILE298
HSD299

ILE198
HSE199

VAL302
LYS305

VAL202
LYS205

TRP320

TRP220

ILE217
HSE218
TYR220
VAL221
LYS224
GLU231
TRP239

ILE324
GLY327
TYR328

ILE224

ILE243

TYR228

TYR247

2.3.6 Receptors secondary structures data. G2 maintains the partial TM1, the
hairpin at extracellular loop2 of 7TM and G1 lost the hairpin when binding with
morphine. To investigate the secondary structure of the receptors, the abundance over
the trajectory is shown in (Figure 6). In the six complexes, 0TM helices maintains and
subtle differences are identified. Notable features are as follows: A). the partial TM1 of
G2 maintained in the two complexes with morphine and IBNtxA. B). Morphine-G2
complex showed a 4.02 % β-strand component compared to negligible values in case of
G1 and wild type receptors, indicating the unfolding of the hairpin at the extracellular
loop2 in these two systems. IBNtxA binding to its wild type and other two splice variants
showed three closely related SS components with an average of 4.1%. C). For MorphineG1 complex, a part of TM2 and TM6 is unfolded. These structural changes can contribute
to the loss of activation by morphine on G1 receptor. D). For IBNtxA, the helical
content at the intracellular loop 2 are different for the the receptors, in the order of
G2>G1>7TM. For IBNtxA, the coil content at the intracellular loop3 are different for the
three receptors, in the order of G1>G2>7TM.
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Figure 6. Protein Secondary structure profile of three receptors complexes with Morphine
(A) and IBNtxA. (B).
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2.3.7 Receptors dynamic responses for the same ligand. Receptor protein Cα
Root Mean Square Fluctuation (RMSF) values are shown in (Figure 7 A and B) for the
Morphine and IBNtxA with G1 and 7TM complexes. We observe the general trend that
the most rigid parts of the receptor (i.e. helices) exhibit lower RMSF values while loose
structures such as the N and C terminals and intra and extra cellular loops show high
RMSF values. In addition, subtle differences are identified for the different receptors in
complex with the same ligand, these differences mainly located at the flexible part of the
receptors. Given the different biological responses of the different receptors in response
to the same stimulating ligand, these dynamic differences could contribute the different
biological responses by modulating the interaction between the receptor and down-stream
signal transduction proteins such as G-protein and or β-arrestin. Being major players in
signal transduction, both the intracellular loop 3 and extracellular loop 2 receptor
conformational changes were further scrutinized and compared. For the morphinereceptor complexes, intracellular loop 3 fluctuation intensities of three receptors were in
the following order: G1>7TM; and similar order was observed for extracellular loop 2
fluctuation.
For the IBNtxA-receptor complexes, the intracellular loop 3 fluctuation intensities of the
three receptors were in the following order: 7TM>G1; and similar order observed for
extracellular loop 2 fluctuation. It appears that the lower the fluctuations are correlated
with the receptor activation by morphine and IBNtxA.
We also inspect the different dynamic responses of the same receptor by the two
different ligands in (Figure 8A and B). Where 7TM shows similar response to both
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morphine and IBNtxA, G1 have larger fluctuation when binding with morphine than that
with IBNtxA.
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Figure 7. RMSF diagrams of receptor Protein C-α. Diagram (A): Morphine-7tm-G1
protein C-α RMSFs comparison. Diagram (B): IBNtxA-7TM-G1 protein C-α RMSFs
comparison. The residue index is shown for the full-length wilt type MOR-1 receptor. In
case of G1 receptor, the RMSF diagram starts at the TM2 skipping TM1 as result of
truncation.
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Figure 8. RMSF diagrams of receptor Protein C-α. Figures (A), (B) represent 7TM and
G1 Receptors Interaction with both IBNtxA and Morphine Comparisons. Each receptors
pairs were aligned using maestro alignment tool.

2.3.8 Ligand fluctuation (L-RMSF). When the same ligand binds to different
receptors, its conformation dynamics might be different. To investigate this, the ligand
RMSFs for morphine and IBNtxA are shown in (Figure 9). Interestingly, the RMSF
profile of Morphine in the complex with 7TM significantly differs that with G1 and G2,
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and the RMSF profiles of morphine with G1 and G2 are very similar. Likewise, IBNtxA
L-RMSF plots differs between 7TM and both G1 and G2, and was similar for G1 and G2.

Figure 9. Ligand RMSF diagrams of Morphine binding to three different receptors.

2.4 Discussion and Conclusion
The compelling side effects and rising addiction rates of current opioids such as
morphine necessitates more research to explore novel morphine replacement and μopioid receptors. Recent genetic study (62)has shown that the MOR-1 gene has
alternative splicing leading to alternative 6TM receptors that lacks of TM1, including G1
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and G2 and Mu3. Furthermore, recent in vivo studies (63) supports the pharmacological
potency of synthetic Morphine analogue (IBNtxA) on mice 6TM alternatives. According
to the mouse knockout model (64)Morphine analgesia is lost in exon 1 knock out model
but reserved in exon 11 knockout. However, IBNtxA analgesia is retained in exon 1
knockout model and lost in exon 11 knockout. Therefore, the study on the structural,
dynamics and interaction with ligand of 6TM will greatly advance IBNtxA analgesia.
Although the crystal structures of 7TM with ligands are available, the high-resolution
structures of 6TM with ligands are not available. A recent MD study have been recently
performed on human Mu receptor wild type and G1 receptor in complex with morphine
previously (65)While this study provided crucial information about the dynamics of the
intracellular loop 3 in both G1 and wild type Mu receptors, other structural and dynamic
differences were not illuminated. Additionally, the G2 receptor characteristic and IBNtxA
binding properties was not explored previously. In this study, we probe the dynamic and
structural properties of G1, G2 and 7TM in complex with morphine and IBNtxA.
Because the interaction between morphine and 7TM has been widely studied
experimentally and computationally. We want to validate our results on the morphine7TM complex against several early studies. Most recently, resolved crystal structure of
murine receptor in complex with BU72 is coincided with our most abundant structure
after doing alignment with human sequence equivalents. Being a small and compacted
molecule, morphine could adopt different binding poses within the pocket; however, the
key residues involved in our binding pose have been consistent with most of previous
experimental and theoretical studies. For example, the most important interaction
observed in early studies (66-69) was a salt bridge formed between morphine’s cationic
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moiety (the tertiary amine) with ASP147 of mouse which corresponds to (ASP149) in
human MOR-1. Our model confirms that morphine’s cationic moiety is interacting with
the ASP149 in Human 7TM MOR-1 receptor. A second important interaction was
hydrophobic interaction between the phenyl group of morphine with TYR298 and TYR
328 which is also consistent with previous experiments which reported TYR299 and
TYR326 of mouse MOR-1 as interacting residues(69-71). Another important interaction
was observed between the aromatic ring of morphine with the sidechain of ILE324 and
ILE298, which was also consistent with most of the previous studies (68,70,72). Most of
the residues contacting morphine molecule (including the most crucial residue ASP 149)
from our study are consistent with previous experimental and computational studies (7376).
Interestingly, these important interactions are not observed in our binding pose between
morphine to hMOR-1G1. Therefore, the change of the binding pose might contribute to
the loss of analgesia on the 6TM variants in the exon 11 knockout model. Similarly, the
residues of hMOR-1 interacting with IBNtxA are quite different from the residues of
hMOR-1G1 interacting with IBNtxA. Again, these differences might contribute to the
loss of analgesia of IBNtxA on hMOR-1G1. Interestingly, the salt bridge between
ASP149 and the cationic moiety of IBNtxA is retained for hMOR-1 and hMOR-1G1.
This interaction might be necessary for activating the receptor. Those detailed
interactions can help us design point mutations to decipher the interaction mechanism
using experimental techniques in the future.
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Our homology modeling indicated that G1 is completely missing the first TM1 while G2
is only partially truncated possessing extra 20 amino acids in N terminal region of protein
(Fig 2). This raised interesting questions on whether the partial TM1 helix is stable,
whether it cause G2 significantly different from G1 and 7TM in term of receptor
activation. Our simulation data indicates this partial helix of TM1 of G2 is stable in the
two simulations in complex with morphine and IBNtxA (Figure S13). Our energetic,
structural and dynamic data strongly support G2 are different from 7TM and G1. First,
our MMGBSA binding data indicates that G2 binding to morphine is weaker than 7TM
by 7.2 kcal/mol but is stronger than G1 by 11.5 kcal/mol. When binding to IBNtxA, G2 is
weaker than both 7TM and G1 by 16.4 kcal/mol and 32.3 kcal/mol, respectively.
Therefore, G2 might not be activated potently by both morphine and IBNtxA. The former
is support by the fact morphine do not activate 6TM variants. The latter requires further
testing of IBNtxA on G2 separately rather than the 6TM mixtures in the original test (64).
Second, our clustering data show the binding pose of morphine and IBNtxA on G2 is
slightly different on 7TM and G1 (Figure 5 and 6). Third, our secondary structure data
show that G2-morphine complex maintained the hairpin at the extracellular loop 2, while
7TM and G1 did not (Figure 7). For G2-IBNtxA complex, its intracellular loop 2 has
slightly higher helical content than G1 and 7TM. Fourth, our protein Ca-RMSF data
show that the G2 profile with morphine and IBNtxA differs significantly from G1 at the
intra-cellar loops 2 and 3, and the extracellular loop 2 (Figure 8). Because these parts are
critical in the signal transduction, different RMSF profiles may suggest different receptor
activation profiles.
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Figure 10. A schematic detailed atom interaction with protein residues Comparison.
Interactions that persists more than 30% of simulation time are shown.
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To understand the significant differences between 7TM and G1 in terms of ligand
activation, and pharmacological actions, we performed both receptor and ligand based
comparisons. Our MMGBSA binding data shows that IBNtxA binding affinity to G1 is
significantly higher than 7TM; this is consistent with the in vivo data that IBNtxA can
activate G1 in exon 1 knockout model while analgesia is lost in 7Tm, which contain exon
11 knockout. In contrast, as expected, morphine exhibited higher affinity to its wild type
compared to G1. Our MD data shows that IBNtxA and Morphine exhibit significantly
different binding poses as indicated from their most abundant structures (Fig 4).
Moreover, when we aligned the complexes of the same ligand, it can vividly be seen that
IBNtxA and Morphine have different binding pose on 7TM and G1 (Table 3). This
evidence is further reinforced when we examine the 2D interaction profile of each ligandreceptor complex (Figure 6). Major interactions for morphine on 7TM are observed in
TM 3 and TM6 which previously suggested to contain the ionic lock responsible for
GPCR activation(77).However, when interacting with G1, morphine interacted with
different residues (Figure 5). Likewise, IBNtxA 2D binding profile clearly indicated that
IBNtxA interface differs significantly between G1 and 7TM receptor. More importantly,
(Fig 5A) 2D interaction which monitors the highly interacting residues (more than 30%
of the simulation time) clearly indicates that Morphine was able to make strong
intermolecular forces with its surrounding lining 7TM pocket .These forces which
including one pi-pi stacking and two cationic- can be better translated in term of binding
energies which previously showed that both VDW and lipophilic are two major
contributing components of the total binding energy Table 2. On the other hand, IBNtxA
binding to same 7TM receptor was not only showing different residues from different
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transmembrane, its binding forces were being mostly H-bonds, which might explain why
it cannot activate this receptor.
Another important observation from the 2D interaction table is that secondary
structures (E2) might influence IBNtxA receptor activation particularly in G1 receptors.
Our MD simulation secondary structure analysis also indicated whereas the hairpin at
extracellular loop 2 was stable in G1-IBNtxA Complex but was unfolded in 7TMmorphine complex. This leads us to speculation that this E2 plays important role in
IBNtxA selectivity and binding .This is consistent with previous experimental studies of
NMR and mutagenesis which confirmed the crucial role of E2 in ligand allosteric and
orthostatic activations (78-80).Moreover, our IBNtxA MD trajectories movies clearly
shows E2 persists as Cantilever umbrella capping the extracellular binding pocket .This
was true most of the simulation time. This is supported by previous Rhodopsin research
where N terminus and E2 were folding together forming a lid for ligand binding pocket.
(63).
Morphine and IBNtxA induced different receptor responses (Figure 9). This is
obvious form the pattern of RMSF fluctuations induced by morphine and IBNtxA on
7TM and G1 receptors. This reinforce our hypothesis that truncation has affected the
conformational and structural priorities of spliced variants and eventually affected their
ligand affinities preferences. The suggested mechanism of action of the GPCR including
the opioids receptors involve the activation of the second and the third intracellular loops
and the proximal portion of the C terminal(65,74,81). According to our protein Cα RMSF
data, I3 and I2 loops fluctuations distinctly different in G1 and 7TM. In case of Morphine
bound G1 receptor, Although I3 loop was showing the highest flexibility compared to
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7TM, it was incapable to influence the cAMP as robust manner as the Morphine effect on
7TM receptor even at higher doses as indicated by biological tests(65). This paradox is
attributed to the fact that I3 activation is only one part of the total signal transduction
pathway in GPCR. It still unclear whether G1 receptor will utilize the classical G-protein
coupling or the B-arrestin in case of Morphine and IBNtxA. Previous research studies
revealed that IBNtxA might exert even excitatory effect on G1 splice variant receptor
contrary to the acknowledged fact of its high efficacy in triple KO mouse(36,65).
The results of partially or total absence of one transmembrane in wild type GPCR
scaffold conferred structural and dynamic alterations in receptor capacity to interact
different ligands .Although the differences between Mu receptors subtypes is subtle
specially G1 and G2,MD simulation experiments could successfully provide evidence
that truncated versions G1 and G2 are uniquely different from WT .Moreover, Morphine
and IBNtxA preferential affinity toward their WT receptors was obviously noticeable
from predicted energy calculations. .This encourages future attempts to design library of
compounds selective to G1 and/or G2 receptors to achieve high efficacy and lowest side
effects.
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Chapter 3
Computational analysis of Amsacrine resistance in human Topoisomerase II alpha
mutants (R487K and E571K) using homology modeling and all atom MD simulation
in explicit membrane
3.1 Introduction
Amsacrine is an Acridine derivative and considered as the first topoisomerase II
inhibitor effective in acute lymphatic leukemia and myeloid leukemia (82).It has
relatively weak DNA binding affinity of 104 M-1 compared to other intercalates such as
Adriamycin, Daunorubicin and Actinomycin –D with affinities range between 105-106M-1
(83) . Unlike etoposide which inhibit selectively topoisomerase Beta subtype,
Amsacrine is equally effective in both subtype A and B of Topoisomerase II enzyme
(84). Amsacrine molecule consists of two moieties; the intercalative Acridine moiety
attached to 4′-amino-methanesulfon-m-anisidide head group (85) (Figure 11A). While
intercalative part is important to anchor the molecule between the DNA base pairs, it is
not sufficient to induce the enzyme inhibitory action by its self without the support of the
second head group moiety. On the other hand, the head group have shown be effective in
stimulating DNA session as standalone molecule without the help of intercalating body.
Although this was happening at higher concentrations, it clearly indicates Amsacrine
head group is critically important in its mechanism as inhibitor. (85) Overall, Amsacrine
stabilizes cleavage complex with DNA via interaction of its head group with top2
residues (86) and DNA intercalation (87)Amsacrine intercalation pattern is shown in
(figure 11C). However, cancer cells can circumvent the inhibitory mechanisms utilizing
mutations, which ultimately confers resistance (88,89). Previous in vivo studies
successfully analyzed two important point mutations (R487K and E571K ) in leukemia
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cell line(90) (Figure 11B). Results conferred Amsacrine Resistance was identified in vivo
as >100-fold and >25-fold resistance in case of R487K and E571k respectively. Previous
functional studies had confirmed the reduced cleavable complex formation as resistance
mechanism for those two mutants (90). However, none of the previous studies illustrates
how mutations reduced the stability of the cleavable ligand-DNA-protein complex. In this
study, we sought to utilize the MD simulation method to study this mutational impact on
the stability of the cleavable complex of human top2a homolog. We study top2a rather
than top2b, because top2b is required for normal physiological function and its inhibition
cause adverse effects (91). We constructed amsacrine-DNA-top2a complex based on the
previously published crystal structure of top2beta (3Qx3). The wild type complex
structure was used to introduce two mutants (R487K) and (E571K). The three complexes
were subjected to 500 ns molecular dynamics simulation for each system. Our MMGBSA binding energy calculations indicated a significant weakening of Amsacrine
affinity toward its wild type compared to two mutants. Our clustering analysis indicates
the changes of the binding poses upon the two point mutations. In particular, the DNA
intercalation was completely and partially lost In R487K and E571K mutants structure
respectively and a ligand was diffused away from its binding site in R487K. Additionally,
the RMSF results for protein receptors were referring to higher structural and
conformational changes in mutants protein structures compared with wild type.
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Figure 11. Structure of Amsacrine (A), amsacrine-Top2α complex (B) and Amsacrine-DNA
complex(C). Human Top2α complex model was based on the crystal structure of Top2β (PDB
id: 3QX3). Two point mutations that cause drug resistance are indicated in red and yellow
triangles (B).
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3.2 Computational Materials and Methods
3.2.1 Human Topoisomerase IIα structure homology modelling. Crystal
structure of Human topoisomerase IIβ in complex with etoposide (pdb code 3QX3) (92)
was used as template to build hTop2α homology model. Prime utility (93,94)
implemented in Maestro was used to build TOP2A structure homolog based on human
hTop2α FASTA sequence from Uniprot (43). The final homolog complex structure was
obtained by docking two prepared Amsacrine molecules into hTop2α using Glide XP
implemented in Maestro(5,46) .The complex was prepared using maestro protein
preparation wizard, optimized and minimized. The same structure was used as primary
structure of hTopIIα. This structure was used to introduce two mutants (R487K) and
(E571K) in both A and B chains of hTop2α homolog.
3.2.2 Molecular dynamic (md) simulations.
Simulation system setup. All three molecular dynamic simulation systems were
built using the prepared and refined receptor-ligand complexes from the XP docking as
input files. In each complex, System was built using SPC as solvent model (48) using
orthorhombic solvent box .Buffer was used as the method of solvent box size calculation
.System was neutralized using Na+ ions, and was added with a salt concentration of 0.15
M NaCl. After the system was successfully solvated, OPLS3 force field (45) (3) was
used to represent the receptor-ligand.
Relaxation and simulation protocols. Desmond simulation package (3) was used
to run all simulations, systems were first relaxed using the default Desmond relaxation
protocol. After Simulation for 1.5 ns under the NPT ensemble with no restraints, the
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relaxed systems were assigned a 400 ns production run conducted under the NPT
ensemble for each of the three systems using the default protocol. M-SHAKE (51) was
applied to constrain all bonds connecting hydrogen atoms, enabling a 2.0 fs time step in
the simulations. The k-space Gaussian split Ewald method (52) was used to treat longrange electrostatic interactions under periodic boundary conditions (charge grid spacing
of ~1.0 Å, and direct sum tolerance of 10–9). The cutoff distance for short-range nonbonded interactions was 9 Å, with the long-range van der Waals interactions based on a
uniform density approximation. To reduce the computation, non-bonded forces were
calculated using an r-RESPA integrator (53) where the short range forces were updated
every step and the long range forces were updated every three steps. Temperature was
controlled using the Martyna-Tuckerman-Klein Nosé-Hoover chain-coupling scheme
with a coupling constant of 1.0 ps. The trajectories were saved at 40.0 ps intervals for
analysis. All MD simulations were performed under 300 K and 1 bar conditions.
Molecular dynamic simulations convergence. To explore whether MD
simulations trajectories were equilibrated toward the end of simulation time, we
investigated the protein Cα RMSD plots from the raw data for each trajectory (Figure
S3). Clearly, plots indicate the convergence of Cα RMSD diagram of all three complexes,
which refers to the state of equilibrium of receptor proteins C alpha at the end of
simulation time. This indicated a conformational stability of receptor throughout the
simulation.
Trajectory clustering analysis.RMSD- based clustering was used to group
Frames from Desmond trajectory (54) implemented in Schrodinger Software .The
merging distance cutoff used was 2Å .This tool performs hierarchical clustering on
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structures from a Desmond trajectory based on the RMSD matrix of a specified set of
atoms [Schrodinger scripts]. The centroid structure (i.e. the structure having the largest
number of neighbors in the structural family) was used to represent the family. The
centroid structures of populated structural families (>1% of total structure population) are
shown in (Figure S2) of the supporting material.
3.2.3 Binding energy calculations and decompositions. Binding energies were
calculated as MMGB-SA using VSGB 2.0 solvation model (4). Frames from the last
20ns were used for this purpose .The net free binding energy calculation was performed
for three complexes: (Ligand +Protein +DNA),( Ligand+ Protein) and (Ligand
+DNA).For simplicity the previous terms were denoted LDP ,LD and LP respectively .In
all three calculations , the same number of frames were selected to get consist binding
free energy predictions . MM-GBSA calculation procedure consists of energy
calculations and energy minimizations as follows: Receptor alone (minimization), Ligand
alone (minimization), Receptor-ligand complex (minimization), Ligand extracted from
optimized receptor-ligand complex (energy calculation), Receptor extracted from
optimized receptor-ligand complex (energy calculation).The total binding free energy
equation is:
ΔG (bind) = Ecomplex (minimized) - ( Eligand(minimized) + Ereceptor(minimized) ).
Decomposition of binding free energy values are also reported in each
calculation. It includes electrostatic, van der walls, hydrophobic, and composition
interactions allows for a more detailed understanding of the effect that resistance places
on each complex.
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3.3 Results
Because hTop2a is a homodimer, we were expecting quantitative results from the
MD simulation to be similar in two chains. However, in most parts, there were
differences between the two subunits ranging from subtle to significant .Therefore, we
sought to take the average value of the two chains to simplify the comparison between
them.
3.3.1 Amsacrine binding energy calculations. Predicted binding energy of
Amsacrine indicated significant affinity weakening in two mutants compared to wild type
hTOP2A. hTOP2α contains two binding DNA intercalation sites which required two
separate binding energy Calculations to investigate the mutational impact on each site
.The MMGB-SA results are charted in (table 4) . The energy of binding ΔG of WT-LDP
was calculated to be (-71.81 Kcal/mol) and (-60.93 Kcal/mol) in binding site A and B
respectively. The E571K mutation impaired LDP binding affinity to be (-42.85 Kcal/mol)
and (-53.5 Kcal/mol) in site A and B respectively. Moreover, R487K mutation attenuated
binding affinities of LDP to be (-39.1 Kcal/mol) and (-34.8 Kcal/mol) in sites A and B
respectively. To get more insight into the mutational impact of ligand on DNA and
Protein interactions, additional MM-GBSA calculations for LD and LP were performed
.As can be seen from the (table 4) ,In E571K mutant,the average cost of energy binding
of Ligand-protein (LD) of was significantly higher than energy needed for Ligandprotein(LP) interaction (-20.85 Kcal/mol Vs -27 Kcal/mol). while the opposite was true
for R487K where Ligand-DNA intercalation required less energy of binding compared to
ligand –protein interaction (-21.5 Kcal/mol Vs -14.9 Kcal/mol .Another important result
was gained from the MMGB-SA decomposition of complexes (Table 4) which clearly
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indicated the significant contribution of both van der Vals forces and Lipophilic terms as
major component of binding energy for all complexes. While, ΔGBELE contributed less
favorably to total binding energy magnitude.

Table 4
Average MM-GBSA binding energies of Amsacrine with hTOP2a WT and Mutants (kcal/mol).

WT

ΔG Type
1
2

ΔG

ΔΔG

LDP LD

R487K

LP

LDP

LD

E571K

LP

LDP

LD

LP

-66.4 -31.9 -32.7 -37.0 -21.5 -14.9 -48.2 -20.9 -27.1
0.0

0.0

0.0

29.4

10.4

17.7 18.2

11.1

5.6

3

ΔVDW -56.3 -33.8 -22.1 -42.5 -27.5 -24.0 -46.4 -27.5 -18.9
ΔΔVDW 0.0 0.0 0.0 13.8
6.3
-1.9 10.0
6.3
3.2
4

ΔLIPO -25.9 -7.9 -17.6 -8.6
ΔΔLIPO 0.0 0.0 0.0 17.3
5

ΔGBELE 15.8
ΔΔGBELE 0.0

9.8
0.0

7.0
0.0

14.1
-1.7

-2.2
5.8

-6.4 -19.1
11.2 6.8

-2.7
5.2

-16.3
1.3

8.2
-1.6

6.5 17.3
-0.6 1.4

9.4
-0.4

8.2
1.1

ΔG: MM-GBSA binding energy (Complex − Receptor − Ligand).
ΔΔG: Relative binding energy with reference to the WT complex.
3
ΔVDW: Change of van der Waals energy (vdW + Pi-pi stacking +Self-contact correction) in gas phase upon complex formation
4
ΔLIPO: Change of lipophilic term (Lipophilic energy) upon complex formation.
5
ΔGBELE: Change of electrostatic interactions (GB/Generalized Born electrostatic solvation energy+ ELE/Coulomb energy
+Hydrogen-bonding) upon complex formation.
LD: Ligand-DNA only Interaction, LP: Ligand-Protein only Interaction, LPD: Ligand-Protein-DNA interaction
LD: Ligand-DNA complex, LP: Ligand-Protein complex, LPD: Ligand-Protein-DNA complex.
Note: Binding energy calculated based on average values from two subunits A and B.
1
2

3.3.2 Amsacrine binding poses and 2D interaction diagram. Two mutants
adopted different biding pockets and poses compared with wild type. To explore
mutational impact on Amsacrine binding pose and ligand interaction network change ,
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we have extracted the most abundant structure of each complex and aligned them using
prime implemented in maestro .The three ligands were superimposed according to the
protein sequence alignments to visualize the nuance differences between the wild type
and mutants structures. We formulated comparison table of all residues contacting the
Amsacrine for three different complexes. Obviously, Amsacrine lost most of the
interacting residues in case of two mutants as seen in (table 5) and sought to bind to
residues significantly different from the wild type .This was clearly noticeable in R487K
mutation which exhibited the highest binding affinity weakening .We noticed that
Amsacrine in chain B in this mutations started forming new interactions in the 400
residue range of receptor which was absent in case of the wild type. This binding
deviation was further verified by observing the significant change in binding poses of
Amsacrine in two mutants (in both binding sites) compared with wild type (Figure 12
A,B,C,E).
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Table 5
Interacting residues with Amsacrine.
WT-A

LYS 436

WT-B

R487K-A R487K-B E571K-A E571K-B

LYS 436

GLH 461 GLH 461 GLH 461
ASP 463 ASP 463 ASP 463
SER 464 SER 464
LEU 486 LEU 486 LEU 486
ARG 487 ARG 487
LYS 487
GLY 488
LYS 489
ASN 504

ARG 434
ILE 435
LYS 436
GLY 437
ILE 438
PRO 439
LYS 440
LEU 441
GLH 461
GLY 462
ASP 463
SER 464
PRO 485
LEU 486

LYS 440
GLH 461
ASP 463
SER 464

ARG 487

LEU 486
ARG 487

LYS 487
GLY 488

ALA 505
GLH 506
GLU 506
LYS 743
TYR 757
HIS 759
GLY 760
GLY 760
GLU 761
GLU 761
MET 762 MET 762 MET 762
SER 763 SER 763 SER 763
LEU 764
MET 765 MET 765
ILE 766
MET 766 MET 766
THR 767
MET 769 ILE 769
LYS 798
SER 800 SER 800
ALA 801 ALA 801
SER 802 SER 802 SER 802
PRO 803 PRO 803
ARG 804 ARG 804 ARG 804
TYR 805
TYR 805

MET 762

GLU 761
MET 762

MET 762
SER 763

MET 765
MET 766

MET 766

SER 800
ALA 801
SER 802
PRO 803
ARG 804
TYR 805

ARG 804
TYR 805

LYS 798

SER 802

TYR 805
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Figure 12. (A-C) Representatives of the most abundant structure families of the three
complexes. (D) Superimposition of the three complex structures. (E) Superposition of
ligand-DNA complexes (WT, E571K and R487K are in green, blue and yellow).

3.3.3 Amsacrine-DNA intercalation changes. Two mutants exhibited significant
DNA intercalation changes compared with wild DNA. For each of the simulation system,
the most abundant structure was extracted using clustering method which group frames of
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trajectory based on merging distance cutoff (54) .After aligning each representative
structure of mutants and wild type, we sought to compare the DNA conformational
changes with respect to Amsacrine in each complex. Results from the two mutants clearly
shows the loss of intercalation state of Amsacrine partially (in case of E571K and
completely (in case of R487K) as seen in figure 13 which shows the detailed picture of
DNA cleavage site.
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Figure 13. Amsacrine-DNA intercalation Changes of the R487 (B1, B2) and E571K(C)
Mutations Compared to Wild Type (A).R487K. B1 and B2 represent the front and rear
views of DNA showing the two-ligand intercalation changes. All three complexes
represent 3A° cutoff distance from the ligand.
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3.3.4 Enzyme protein Cα RMSF analysis. Enzyme protein Cα RMSF analysis
indicated significant conformational changes in both mutants compared to wild type
enzyme. The Root Mean Square Fluctuation (RMSF) is useful for detecting local changes
along the protein chain. (RMSF) Diagrams of each binding site of the three complexes
were combined in one diagram for comparison purpose (Figure 14). Results clearly
shows that for the most part, R487K mutation reflected the highest fluctuation pattern
compared to E571K mutation, which in turn was higher than WT level (figure 14). This
clearly indicates the significant conformational changes in protein structure upon
mutations, which contributes to the weakening effect of the mutation. Furthermore, the
dominant fluctuation pattern in both binding sites was consist with the secondary
structure distribution of the enzyme structure where loops and turns are exhibiting the
highest dynamic effects compared to alpha strands.

14
12

Chain B

Chain A

8
6
4
2
0

0
41
82
123
164
205
246
287
328
369
410
451
492
533
574
615
656
697
738
779
820
861
902
943
984
1025
1066
1107
1148
1189
1230
1271
1312
1353

Protein RMSF (A°)

10

Residue Index
WT_AB

R487K_AB

E571K_AB

Figure 14. Protein Cα RMSF diagrams of hTop2α WT and mutants upon Amsacrine
Binding. Residue from 1 to 645 represent the chain (A) of enzyme while residue 646 to
1330 belongs to chain (B).
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3.3.5 Ligand conformational change (L-RMSF).Ligand conformational change
indicated different configurations and higher intensities in two mutants compared to wild
type. Ligand RMSF shows the ligands dynamic fluctuations with respect to protein
broken down by atomic contribution of ligand molecule. It gives insights about the
entropic contribution endured by the ligand during protein interaction. According to our
ligand RMSF comparison diagram, the general pattern of fluctuation is significantly
higher for the mutants compared to the wild type. More importantly, R487K mutant
showed higher ligand fluctuation than E571K mutant (Figure 15). Another worth
mentioning is the region of the Amsacrine molecule exhibiting higher fluctuation.
Obviously, the highest fluctuations are seen in the first and the last part of L-RMSF plot,
which corresponds, to the 3-methoxy group of m-AMSA and the 4′-aminomethanesulfon-m-anisidide head group, which are loosely connected groups. However,
unexpectedly, another high fluctuation was observed at the middle of the plot, which
correspond, to the third ring of acridine moiety in Amsacrine responsible for active
intercalation inside DNA grove.
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Figure 15. Average ligand RMSF for the three complexes. Complexes were aligned and
superimposed using Maestro software.

3.4 Discussion and Conclusion
Previous study identified two point mutations (R487K and E571K ) of human
Top2α in leukemia cell line (90). The vivo essays conferred more than 100-fold and 25fold resistance to Amsacrine for R487K and E571K respectively. Reduced cleavable
complex formation was identified to be the resistance mechanism. However, detailed
molecular and structural mechanisms underlying this resistance remains to be elusive. We
have applied homology modeling and MD simulations to mechanically understand
mutational impact on the complex structure and stability.
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Our MM-GBSA binding data indicated the significant weakening of Amsacrine binding
affinities toward two mutants compared to wild type as seen in (table 4).The binding
energy decrease caused by R487K mutation is larger than that by E571K, indicating that
R487K can cause higher fold of drug resistance than E571K by a bigger reduction of the
ternary complex formation. This fold change order is consistent with the experimental
result, which indicated 100 and 25 fold drug resistance for R487K and E571K
respectively. (95) When decomposing the overall ligand binding into ligand-DNA (LD)
and ligand-protein (LP) interactions, we observed different contribution pattern for these
two mutants. In R487K mutation, a ΔΔG value of 17.7 kcal/mol in LP suggested
significant impairment of ligand interaction with protein TOP2α. This is likely the direct
impact of the mutation on the protein’s ability to form intermolecular interaction with
Amsacrine, because R487 is one of the major contributors to Amsacrine protein
interaction in the wild type(86). This also emphasizes the role of Amsacrine molecule
head group in forming the ternary complex (85). On other hand, ΔΔG of LD in R487K
(i.e. 10.4 kcal/mol) is much lower than change in LP (i.e. 17.7 kcal/mol), indicating that
ligand-DNA interaction contributes less than ligand-protein interaction to overall ligand
binding energy decrease. In E571K, decrease of LP (5.6 kcal/mol) is much smaller than
decrease of LD (11.0 kcal/mol), indicating that change of ligand-DNA interaction plays
bigger role in the overall decrease of the ligand binding energy. This might be explained
by the fact that E571K is located far away from the ligand-protein binding site and thus
cause smaller perturbation on ligand-protein interaction. When comparing R487 with
E571, the larger LP weakening in R487 is consistent with higher fold resistance
compared to E571K.
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Another significant impact of the mutations envisioned through our MD
simulations were the Amsacrine-DNA intercalation changes as can be seen from the most
abundant structures of mutants and WT DNA (Figure 13A). For example, the Amsacrine
Molecule moiety was diffused away and relocated to be outside the DNA binding groove
as seen in E571K (figure 13C) . As such, Amsacrine inhibitory effect was lost because
both intercalating ability and protein binding were abolished and Top2a might be religated and thus recovered. This agrees the previously published experimental studies that
established the role of Acridine moiety in Amsacrine to anchor it into the DNA groove.
(83,85,87)
The mutations also lead to the changes of ligand-protein binding poses, which can
be seen in the ligand 2D diagram in (Figure S3) and (Table 5). The most significant
changes can be observed in R487K chain A and B where protein established new contacts
with ligands in certain regions while lost some in other regions. Likewise, the binding
poses comparisons indicated the significant changes in ligand binding pose with respect
to protein which clearly can be seen in chain B of WT and two mutants Figure S3. These
results is consistent with the role of Amsacrine as an enzyme poison (85) in addition to a
DNA intercalator.
The protein RMSF profiles further showed the changes of protein dynamics due to the
mutations. In both mutants, RMSF diagram fluctuation intensity was higher compared in
WT enzyme. Although this RMSF profiles from on crystal structure of a lesioned DNA
with Amsacrine were DNA was pre-nicked with Top2 and cleaved; it clearly shows
larger fluctuation of mutant protein structure can cause disruption in network of residues
at Amsacrine binding site as seen in Figure 13. More importantly, the fluctuation was
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observed higher in R487K than E571k which was higher than WT. This was also
supported by the RMSF averages which also was in agreement with the previous order. It
appears that the larger protein fluctuation might be required for the normal function of the
enzyme. Our data showed the active role of two key residues ARG487 and GLU571 in
maintaining protein backbone integrity and subsequent propagation of the conformational
change conferred by these two mutations on protein structure and dynamics (96).
This phenomenon was further pictured via examining the L-RMSF results, which
measures ligand configurational changes in respect to receptor. Results were indicating
the unique pattern and higher magnitude of conformational changes in R487K compared
to WT and E571K mutant (Figure 15). Moreover, regions in Amsacrine molecule of high
fluctuation were mainly the 3-methoxy group and the 4′-amino-methanesulfon-manisidide head groups. The fact that these groups are the major contributors in Amsacrine
binding to protein, a higher fluctuation in these groups can negatively affect the ligandprotein affinity. This is in fact another advantage of MD simulation which characterizes
mutational impact between protein and ligand, since ligand conformational orientation is
essential for proper binding pose and determines the success of intercalation.
Computational tools enabled us to understand the how mutations lead to
resistance through energy calculations and other MD simulation parameters. The two
mutants resulted in binding affinity weakening of Ligand-DNA-Protein complexes of two
mutants in consistent manner with the in vivo fold resistance results .More importantly,
larger drug resistance of R487K than E571K was caused by larger weakening of ligand
protein interaction which agrees with the established Amsacrine inhibitory mechanism
which emphasize the crucial role of protein in maintaining ternary complex with ligand.
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For both mutants, weakening of ligand- DNA interaction also contributed to
destabilization of the ternary complex, a ligand moved out of intercalation was observed
in R487K and E571K could destabilize the ternary complex due to intercalation loss.
Furthermore, MD simulation method could detect the significant changes in binding
poses and 2D interaction diagrams, which also contributed to resistance .MD simulation,
could prioritizes and characterizes the most significant mutation quantitatively and
qualitatively. This is crucial for future drug design of effective ligands to counteract these
mutations. (97)
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Appendix A
Supporting Material (Chapter 2)
Table S1
Glide XP docking score (units: kcal/mol).

Morphine
IBNtxA

hMOR-1
-3.4
-3.3

hMOR-G2
-2.7
-4.1

hMOR-G1
-3.0
-5.4
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Figure S1. Sequences of full-length and truncated variants of human MOR-1 (hMOR-1).
Rectangular boxes refer to the Trans membranes helices. The yellow highlight represents
the amino acids sequences for each transmembrane domain. The intracellular (I1-I3) and
extracellular loops (E1-E3) connecting the Trans membranes are illustrated as threads
labeled according to loop location.
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Figure S2. 3D-structures of morphine, IBNtxA, and their complexes with 7TM, G2 and
G1 hMOR-1 receptors obtained from Glide XP docking. TM1 is colored in purple.
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Figure S3. Root Mean Square Deviation (RMSD) of protein-Ligand complexes against
simulation time. Cα-RMSD is measured using the initial frame as reference, while the
ligand fit on protein RMSD refer to in place RMSD of ligand when protein is aligned.
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Figure s4. MMGBSA binding energies of both Morphine and IBNtxA complexes with
three different receptors. The above columns represent the different components of MMGBSA binding energy (kcal/mol).
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Figure S5. Representative receptor-morphine structures of top structural families from the
clustering analysis. Abundance is annotated. For all structures, the extracellular and
intracellular loops were truncated for clarity. The abundance is annotated.
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Figure S6. Representative receptor-IBNtxA structures of top Complexes structural
families from the clustering analysis. Abundance is annotated.
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Figure S7. Contacts of Morphine to wild type receptor (hMOR-1). The genetic numbering
is annotated for each interacting residue. A: Interactions fraction over the MD trajectory.
B: Illustrates interactions persist more than 30% of simulation time. C: The ligand protein
contacts over the MD trajectory.
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Figure S8. 2D profile data of Morphine binding with G2 splice variant receptor
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Figure S9. 2D profile data of Morphine binding with G1 splice variant receptor
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Figure S10. 2D profile data of IBNtxA binding to wild type receptor (MOR-1).
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Figure S11. 2D profile data of IBNtxA with G2 splice variant receptor.
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Figure S12. 2D profile data of IBNtxA with G1 splice variant receptor

81

82

Figure S14. Secondary structure elements over the simulation time for IbntxA with three
receptors.
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Figure S15. Figure S. RMSF diagrams of receptor Protein C-α. Diagram (A): Morphine7tm-G2-G1 protein C-α RMSFs comparisons. Diagram (B): IBNtxA-7TM-G1-G2 protein
C-α RMSFs comparisons. The residue index is shown for the full length wilt type MOR-1
receptor .In case of G1 receptor, the RMSF diagram starts at the TM2 skipping TM1 as
result of truncation.
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Figure S16. RMSF diagram of receptor Protein C-α .Figures G2 Receptor Interaction with
both IBNtxA and Morphine Comparisons.
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Figure S17. Ligand torsion profile of Morphine binding to three different receptors.
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Figure S18. Ligand torsion profile of IBNtxA when biding to three different receptors.
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Figure S19. Comparison of Morphine-WT Mu receptor (from our experiment) with the
most recent crystal structure (5CM1)
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Appendix B
Supporting Material (Chapter 3)
Table S1
MM-GBSA binding energies of Amsacrine to hTop2α WT and two mutants.
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Table S2
Decomposition of MM-GBSA binding energies of Amsacrine to hTop2α WT and two mutants

WT
R487K
E571K
ΔG Type LDP-A LD-A LP-A LDP-B LD-B LP-B LDP-A LD-A LP-A LDP-B LD-B LP-B LDP-A LD-A LP-A LDP-B LD-B LP-B
1

ΔG

2

-71.81 -36.7 -32.7 -60.93 -27.2 -32.6 -39.13

ΔΔG
0
0
0
0
0
0
ΔVDW -60.46 -37.6 -22.4 -52.23 -30.1 -21.9
ΔΔVDW
0
0
0
0
0
0
4
ΔLIPO -25.53 -8.59 -16.5 -26.18 -7.28 -18.6
ΔΔLIPO
0
0
0
0
0
0
5
ΔGBELE 14.18 9.4 6.16 17.49 10.21 7.89
ΔΔGBELE 0
0
0
0
0
0
3

-24 -15.1 -34.82

32.68 12.73 17.67 26.11

-19 -14.8 -42.85

-21

-22

-53.5 -20.7 -32.2

8.16 17.78 28.96 15.73 10.75 7.44

6.42 0.44

-51.14 -33.1 -18.1 -33.89 -22 -11.9 -44.11 -28.6 -15.6 -48.68 -26.5 -22.3
9.32 4.51 4.34 18.34 8.11 9.94 16.35 8.98 6.85 3.55 3.6 -0.39
-5.57 -0.89 -4.67 -11.54 -3.41 -8.13 -16.25 -2.58 -13.7 -21.86 -2.91 -18.9
19.96 7.7 11.8 14.64 3.87 10.5 9.28 6.01 2.81 4.32 4.37 -0.31
17.57 9.963 7.68 10.61 6.4 5.24 17.51 10.18 7.25 17.05 8.66 9.05
3.39 0.563 1.52 -6.88 -3.81 -2.65 3.33 0.78 1.09 -0.44 -1.55 1.16

ΔG: MM-GBSA binding energy (Complex − Receptor − Ligand).
ΔΔG: relative binding energy with reference to WT complex.
3
ΔVDW: Change of van der Waals energy (vdW + Pi-pi stacking +Self-contact correction) in gas phase upon complex formation
4
ΔLIPO: Change of lipophilic term (Lipophilic energy) upon complex formation.
5
ΔGBELE: Change of electrostatic interactions (GB/Generalized Born electrostatic solvation energy+ ELE/Coulomb energy
+Hydrogen-bonding) upon complex formation.
LD: Ligand-DNA only Interaction, LP: Ligand-Protein only Interaction, LPD: Ligand-Protein-DNA interaction
A&B: refers to the two binding sites.
1
2
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Figure S1. Root Mean Square Deviation (RMSD) of Amsacrine-Enzyme complexes
against simulation time. Cα-RMSD is measured using the initial frame as reference,
while the ligand fit on protein RMSD refer to in place RMSD of ligand when protein is
aligned.
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Figure S2. Representative hTOP2α-Amsacrine structures of top structural families from
the clustering analysis. Abundance is annotated.
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Figure S3. 2D interaction diagrams of Amsacrine with hTOP2α WT and mutants. All
complexes were aligned and superimposed using Maestro software.
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Figure S4. 2D profile data of Amsacrine binding to WT hTop2α Chain A.
(A) Interactions occurring more than 30% of simulation time. (B) protein interactions
with ligands throughout simulation time. (C) Timeline representations of interactions and
contacts.

94

Figure S5. 2D profile data of Amsacrine binding to WT hTop2α Chain B.
(A) interactions occurring more than 30% of simulation time. (B) protein interactions
with ligands throughout simulation time. (C) Timeline representations of interactions and
contacts.
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Figure S6. 2D profile data of Amsacrine binding to R487K mutant Chain A. (A)
interactions occurring more than 30% of simulation time. (B) protein interactions with
ligands throughout simulation time. (C) timeline representations of interactions and
contacts.
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Figure S7. 2D profile data of Amsacrine binding to R487K mutant Chain B. (A)
interactions occurring more than 30% of simulation time. (B) protein interactions with
ligands throughout simulation time. (C) Timeline representations of interactions and
contacts.
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Figure S8. 2D profile data of Amsacrine binding to E571K Chain A. (A) interactions
occurring more than 30% of simulation time. (B) protein interactions with ligands
throughout simulation time. (C) timeline representations of interactions and contacts.
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Figure S9. 2D profile data of Amsacrine binding to E571K Chain B. (A) interactions
occurring more than 30% of simulation time. (B) protein interactions with ligands
throughout simulation time. (C) timeline representations of interactions and contacts.
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Figure S10. RMSF of hTop2α WT and mutants in the complex with Amsacrine. Chain
A sequence is: 0 - 678 .Chain B sequence is: 679 -1361.
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Figure S11. Ligand RMSF for the three complexes.
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Figure S12. The secondary structure elements over the simulation time for the three
complexes. All three complexes were aligned with Maestro software.
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Figure S13. Ligand torsion profile of Amsacrine when binding to chain A of hTop2α WT
and mutants.
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Figure S14. Ligand torsion profile of Amsacrine when binding to chain B of hTop2α WT
and mutants.

104

